Gene Therapy for Infectious Diseases

Bunnell, Bruce A.; Morgan, Richard A.

doi:10.1128/cmr.11.1.42

Cited by 102 publications

(50 citation statements)

References 151 publications

(192 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DNA vaccination represents a promising strategy to protect animals and humans against pathogenic microorganisms, particularly intracellular parasites (Bunell and Morgan 1998), as DNA immunization enables the production of the native form of a given antigen, priming both cellular and humoral specific immune responses (Robinson 1997). Besides, DNA vaccines are attractive because of ease of production and low cost (Bunell and Morgan 1998) and the potential for long-lasting immunity (Gurunathan et al 2000).…”

Section: Discussionmentioning

confidence: 99%

“…Besides, DNA vaccines are attractive because of ease of production and low cost (Bunell and Morgan 1998) and the potential for long-lasting immunity (Gurunathan et al 2000). In this study, we constructed a multiple antigenencoding plasmid pSAG1-ROP2, and then investigated the ability of pSAG1-ROP2 to induce protective immunity in a DNA vaccine strategy with or without co-administration of pIL-12 as a genetic adjuvant.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of the immune response induced by multiantigenic DNA vaccine encoding SAG1 and ROP2 of Toxoplasma gondii and the adjuvant properties of murine interleukin-12 plasmid in BALB/c mice

Zhang

Jiang

et al. 2007

Parasitol Res

View full text Add to dashboard Cite

The heavy incidence and severe or lethal damages of toxoplasmosis clearly indicate the need for the development of a more effective vaccine. In the present study, we constructed a multiantigenic DNA vaccine, eukaryotic plasmid pcDNA3.1-SAG1-ROP2, expressing surface protein SAG1 and rhoptry protein ROP2 of Toxoplasma gondii, and examined the expression ability of the DNA vaccine in HeLa cells by Western blot. Afterwards, we investigated the efficacy of pcDNA3.1-SAG1-ROP2 with or without co-administration of a plasmid encoding murine interleukin-12 (pIL-12) as a genetic adjuvant to protect Bagg albino/c mice against toxoplasmosis. After T. gondii RH strain challenge, mice immunized with pcDNA3.1-SAG1-ROP2 displayed significant high survival rates. Moreover, the protection was markedly enhanced by pIL-12 co-administration. The results of lymphocyte proliferation assay, cytokine, and antibody determinations show that mice immunized with pcDNA3.1-SAG1-ROP2 elicited stronger humoral and Th1-type cellular immune responses than those immunized with single-gene plasmids, empty plasmid, or phosphate-buffered saline. Furthermore, co-immunization with IL-12 genes resulted in a dramatic enhancement of these responses. Our study indicates that the introduction of multiantigenic DNA vaccine is more powerful and efficient than single-gene vaccine, and the co-delivery of pIL-12 further enhanced the potency of multiantigenic DNA vaccine.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Evaluation of the immune response induced by multiantigenic DNA vaccine encoding SAG1 and ROP2 of Toxoplasma gondii and the adjuvant properties of murine interleukin-12 plasmid in BALB/c mice

Zhang

Jiang

et al. 2007

Parasitol Res

View full text Add to dashboard Cite

show abstract

“…Recently, scientists from UCLA reported that a Phase II gene therapy clinical trial showed that cell-derived gene transfer is safe and biologically active in HIV-infected individuals [81]. These efforts are encouraging and support the growing excitement around gene therapy for the treatment of HIV/ AIDS.…”

Section: Gene Therapy For Hiv/aidsmentioning

confidence: 96%

Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS)

Kumar¹,

Kumar²

2014

Nanotechnology and Nanomaterials in the Treatment of Life-Threatening Diseases

View full text Add to dashboard Cite

“…These strategies are known to selectively regulate the expression of disease causing genes by replacing the "abnormal gene" with "corrected gene" or down regulating the expression of associated harmful proteins. [10][11][12] In this manuscript, we have emphasized on the challenges and opportunities involved in the therapy of such intracellular infections, especially employing RNAi-based interventions. We have focused our discussion on the current state-of-the-art RNAi-based therapies, which have been explored for various intracellular infections mediated by bacteria, fungi, viruses and protozoa.…”

Section: Introductionmentioning

confidence: 99%

RNA Interference-Based Therapeutics: Molecular Platforms for Infectious Diseases

Dyawanapelly¹,

Ghodke²,

Vishwanathan³

et al. 2014

j biomed nanotechnol

View full text Add to dashboard Cite

The potential uses and therapeutic benefits of RNA interference (RNAi) are enormous. Recent insights into RNAi technologies have highlighted their role in analyzing the functions and regulation of gene expression in eukaryotes and further utilizing this information for identification and amelioration of many diseases. These studies have also established the role of RNAi mediated post-transcriptional gene silencing (PTGS) mechanism in mammals by several endogenous, gene regulation systems including small interfering RNAs (siRNA), micro RNA (miRNA) and small hairpin RNAs (shRNA). Moreover, these RNAi-based therapeutics have demonstrated the capability to silence therapeutically relevant genes in various in vivo models of cancer, infections autoimmune diseases and other genetic disorders. Over the past few decades, infectious diseases have been one of the leading causes of death around the world. Ubiquitously, intracellular obligate or facultative microorganisms cause serious or fatal infections and associated diseases in humans. Currently available literature suggests that infections caused by intracellular pathogens present an intriguing area, wherein RNAi technology may be effectively employed to neutralize the harmful effects of various intracellular pathogens. In this manuscript, we have emphasized on the challenges and opportunities involved in the therapy of such intracellular infections, especially employing RNAi-based interventions. We have focused our discussion on the current state-of-the-art RNAi-based therapies, which have been explored for various intracellular infections mediated by bacteria, fungi, viruses and protozoa. Nanocarrier mediated delivery of siRNA and shRNA molecules have also been found to overcome the various delivery challenges of these biotherapeutics; these have also been briefly summarized here. Furthermore, the outcomes and progresses that have been made in pre-clinical models and clinical trials have also been presented to review the numerous challenges encountered so far. Finally, we have also addressed the various future perspectives that could overcome these challenges and accelerate the progress and commercial success of these systems.

show abstract

Gene Therapy for Infectious Diseases

Cited by 102 publications

References 151 publications

Evaluation of the immune response induced by multiantigenic DNA vaccine encoding SAG1 and ROP2 of Toxoplasma gondii and the adjuvant properties of murine interleukin-12 plasmid in BALB/c mice

Evaluation of the immune response induced by multiantigenic DNA vaccine encoding SAG1 and ROP2 of Toxoplasma gondii and the adjuvant properties of murine interleukin-12 plasmid in BALB/c mice

Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS)

RNA Interference-Based Therapeutics: Molecular Platforms for Infectious Diseases

Contact Info

Product

Resources

About